United States Continuous Glucose Monitoring Market Forecast 2026–2034

United States Continuous Glucose Monitoring (CGM) Market Size and Forecast 2026-2034

United States Continuous Glucose Monitoring (CGM) Market is expected to reach US$ 22.31 Billion by 2034 from US$ 6.08 Billion in 2025, with a CAGR of 15.54% from 2026 to 2034. The United States CGM market is driven by rising diabetes burden, growing use of wearable monitoring devices, expanding digital health integration, increasing home-based care adoption, and stronger focus on proactive glucose management.

United States Continuous Glucose Monitoring (CGM) Industry Overview

The United States Continuous Glucose Monitoring (CGM) industry is experiencing significant momentum as diabetes care shifts toward continuous, technology-enabled monitoring solutions. CGM systems allow users to track glucose levels in real time, identify trends, and make timely treatment decisions, making them increasingly valuable in both Type 1 and Type 2 diabetes management. Growing awareness of the benefits of continuous monitoring, including improved glycemic control and reduced dependence on fingerstick testing, is encouraging broader acceptance among patients, caregivers, and healthcare professionals. The market is also benefiting from increasing emphasis on preventive disease management, patient engagement, and personalized healthcare delivery across the country.

Innovation remains central to the development of the United States CGM market. Manufacturers are introducing advanced sensors with improved accuracy, longer wear periods, smaller form factors, and seamless integration with smartphones and digital health platforms. Many CGM systems are now designed to support remote monitoring, allowing caregivers and healthcare providers to review glucose trends and respond more effectively to patient needs. Integration with insulin pumps and automated insulin delivery systems is further strengthening the role of CGM in comprehensive diabetes management. In addition, growing interest in wearable health technologies is making CGM devices more attractive to consumers seeking convenient and continuous health monitoring tools.

The care setting for CGM adoption is also expanding beyond hospitals and specialty clinics into homecare and outpatient environments. Patients increasingly prefer monitoring tools that allow greater independence, convenience, and control over their daily diabetes routines. Home-based CGM usage is supported by telehealth expansion, digital health applications, and rising confidence in self-management technologies. At the same time, healthcare providers continue to play a key role in device selection, patient education, and interpretation of glucose data. Although the market outlook remains positive, adoption can still be affected by reimbursement complexity, affordability concerns, and varying levels of patient familiarity with digital devices. Overall, the United States CGM market is positioned for sustained growth as healthcare systems continue to prioritize connected monitoring, chronic disease management, and patient-centric diabetes care solutions.

Recent Developments in the CGM Market

• April 2025: The FDA authorized Dexcom's G7 15-Day system, the longest allowed wear duration with 8.0% MARD, paving the way for an H2 2025 commercial launch.
• March 2025: The FDA issued a warning letter to Dexcom, alleging manufacturing control issues and seeking corrective steps within a given timeframe.

Growth Catalysts Shaping the United States Continuous Glucose Monitoring (CGM) Market

Rising Diabetes Prevalence and Early Diagnoses

According to CDC surveillance, adult diabetes prevalence is rising from 9.7% in 1999-2000 to 15.8% in 2021-2023, implying that 38.4 million Americans could benefit from commercial solutions for continuous glucose monitoring. Younger persons are being screened sooner, which encourages CGM adoption earlier in the disease cycle. Payers are increasingly viewing CGM as a first-line therapy that prevents severe hypoglycemia and costly hospitalizations, making reimbursement justification easier. Providers view CGM as a fundamental self-management tool rather than an advanced add-on, a perspective shift that broadens the addressable audience. As a result, the continuous glucose monitoring market sees sustained volume growth from both Type-1 and Type-2 cohorts, whose treatment programs are now based on real-time data input.

Technological advancements in CGM devices

Technological improvements in continuous glucose monitoring (CGM) devices are significantly driving the US CGM market. Diabetes patients benefit greatly from improved CGM devices available today, which outperform traditional fingerstick monitoring methods. Real-time glucose readings from these devices allow for better diabetes management and assist patients control their blood sugar levels.

Some of the most recent CGM technologies include cutting-edge features such as improved alerts and alarms for hypo/hyperglycemic events. This enables quick response and lowers the danger of potentially fatal glucose swings. The availability of smartphone-compatible CGM devices has increased convenience. Patients can quickly monitor glucose levels and trends on their phones throughout the day. This form of user-friendly connectivity encourages more device use and commitment to therapy.

According to the Centers for Disease Control and Prevention (CDC), nearly 14% of the U.S. population was diagnosed with diabetes in 2018. The increasing prevalence of this chronic illness, together with advancements in CGM functionality and accessibility, are driving up demand. The rapid development and acceptance of innovative CGM technologies is expected to drive further expansion of the US market in the next years.

Expansion of Home-Based and Self-Managed Diabetes Care

The increasing preference for home-based healthcare and self-managed chronic disease treatment is creating strong opportunities for the United States CGM market. Patients are increasingly seeking devices that allow them to monitor health conditions independently while maintaining flexibility in daily routines. CGM systems are well suited to this trend because they deliver continuous glucose insights without requiring repeated clinic visits or frequent manual testing. The expansion of telehealth, remote consultations, and digital diabetes education is further supporting adoption in homecare settings. CGM devices also help patients become more engaged in their own care by enabling them to understand how lifestyle changes and medications affect glucose patterns. As healthcare delivery continues to move toward convenience, accessibility, and long-term disease management outside hospital environments, CGM systems are expected to gain stronger traction among home users and community-based care programs.

Market Restraints Influencing the United States Continuous Glucose Monitoring (CGM) Industry

Cost Pressures and Reimbursement Complexity

Despite strong growth potential, affordability remains a key challenge for the United States CGM market. CGM systems involve costs associated with sensors, transmitters, receivers, replacement supplies, and ongoing monitoring needs, which can create financial pressure for patients requiring long-term diabetes care. Although insurance support has expanded for some user groups, reimbursement structures may still vary depending on the payer, diabetes type, treatment plan, and eligibility criteria. This variation can make access less predictable for certain patients and may delay adoption of CGM technology. In some cases, out-of-pocket expenses can discourage continuous use or prevent users from upgrading to more advanced systems. For manufacturers and healthcare providers, navigating reimbursement processes can also add administrative complexity. Improving affordability, simplifying access pathways, and expanding insurance support will remain important to strengthen long-term adoption and market penetration across broader patient populations.

User Training, Data Interpretation, and Device Acceptance

Another challenge affecting the United States CGM market is the need for user education and confidence in device-based diabetes management. While CGM systems offer significant benefits, patients must still learn how to wear sensors correctly, interpret glucose trends, respond to alerts, and incorporate data into treatment decisions. Some users, particularly older adults or first-time adopters of digital health technologies, may initially find the devices difficult to manage. Concerns around skin irritation, sensor placement, alert fatigue, or technology dependence can also influence acceptance. Healthcare providers often need to invest time in onboarding and follow-up support to ensure effective use. If users do not fully understand the value of CGM data or feel overwhelmed by constant monitoring, adherence may decline. Strengthening patient training, simplifying interfaces, and improving support services will be essential to overcoming these barriers and supporting wider market acceptance.

California Continuous Glucose Monitoring (CGM) Market

California represents a significant market for continuous glucose monitoring solutions due to its advanced healthcare ecosystem, strong adoption of digital health technologies, and high awareness of chronic disease management. The state has a broad network of endocrinologists, diabetes specialists, hospitals, and outpatient care providers that support the adoption of CGM devices across varied patient groups. Consumers in California are generally more receptive to wearable health technologies, which supports the use of real-time glucose monitoring tools in both clinical and homecare settings. The presence of technology-driven healthcare innovation also contributes to faster acceptance of app-connected and remotely monitored CGM systems. In addition, growing emphasis on preventive care and patient-centered disease management is supporting the role of CGM in long-term diabetes control. As connected healthcare and home monitoring continue to expand, California is expected to remain an influential regional market for CGM adoption.

Texas Continuous Glucose Monitoring (CGM) Market

The Texas CGM market is expanding as the state experiences growing demand for advanced diabetes management tools and wider access to modern healthcare services. A large and diverse patient population, combined with increasing awareness of glucose control and chronic disease monitoring, is creating favorable conditions for CGM adoption. Healthcare systems across Texas are gradually incorporating digital monitoring solutions into diabetes treatment pathways, especially for patients requiring close glycemic observation. Homecare adoption is also becoming more relevant as patients seek flexible monitoring options that fit into daily life. CGM devices are gaining attention among individuals who want to reduce dependence on conventional testing and improve treatment decisions through continuous glucose insights. At the same time, provider education and patient outreach remain important to ensure broader understanding of device benefits. With continued healthcare modernization and stronger focus on diabetes care, Texas is expected to contribute meaningfully to market development.

New York Continuous Glucose Monitoring (CGM) Market

New York is an important regional market for continuous glucose monitoring systems due to its well-established healthcare infrastructure, concentration of specialty care providers, and growing focus on integrated chronic disease management. The state supports adoption of CGM devices through access to endocrinology services, diabetes education programs, and hospital networks that increasingly emphasize data-driven treatment decisions. Urban populations in New York are showing greater acceptance of connected health technologies, which supports the use of app-enabled and remotely monitored CGM systems. Demand is also being influenced by patient preference for more convenient, less invasive glucose monitoring tools that can support better lifestyle management. Home-based monitoring is gaining relevance as telehealth and digital care coordination continue to develop across the state. With strong clinical support and increasing awareness of continuous glucose tracking benefits, New York is expected to remain a key contributor to the national CGM market.

Florida Continuous Glucose Monitoring (CGM) Market

Florida’s CGM market is developing steadily with growing demand for chronic disease management technologies, increasing diabetes awareness, and rising interest in home-based health monitoring solutions. The state’s healthcare landscape includes a large population requiring ongoing disease management support, which creates favorable conditions for the adoption of continuous glucose monitoring systems. Patients in Florida are increasingly seeking convenient devices that allow them to monitor glucose trends without repeated manual testing, especially in non-hospital settings. Healthcare providers are also recognizing the role of CGM in improving patient engagement, treatment adherence, and long-term glycemic control. The expansion of outpatient care, remote monitoring, and telehealth services is further supporting the integration of CGM devices into routine diabetes care. As healthcare delivery becomes more decentralized and patient-focused, Florida is expected to see continued momentum in CGM usage across both homecare and clinical settings.

Sensors Continuous Glucose Monitoring (CGM) Market

Sensors form the core of the CGM ecosystem and represent a critical segment within the United States market. These components are responsible for continuously detecting glucose levels and transmitting data to connected receivers, smartphones, or insulin delivery systems. Demand for CGM sensors is closely tied to overall device adoption, replacement cycles, and technological innovation in wear duration, accuracy, and comfort. Manufacturers are focusing on developing compact, skin-friendly, and easy-to-apply sensors that improve patient experience and encourage long-term adherence. Enhanced sensor performance can also strengthen confidence among healthcare professionals who rely on CGM data to guide treatment decisions. As CGM usage expands across homecare, outpatient, and specialty diabetes settings, the sensor segment is expected to remain strategically important. Continued innovation in calibration-free designs, longer sensor life, and integrated data capabilities will play a central role in shaping the future of this segment.

Homecare Settings Continuous Glucose Monitoring (CGM) Market

The homecare settings CGM market in the United States is gaining traction as diabetes management increasingly moves beyond hospitals and clinics into everyday living environments. Patients prefer home-based monitoring solutions that offer convenience, independence, and real-time visibility into glucose fluctuations without repeated facility visits. CGM devices are particularly well suited to homecare because they provide continuous tracking, alerts, and actionable data that can support self-management and caregiver oversight. The growth of telehealth and remote patient monitoring is further reinforcing the value of CGM in home settings, enabling healthcare providers to review glucose patterns and make treatment recommendations without in-person appointments. Families and caregivers also benefit from data-sharing functions that improve confidence in managing chronic conditions at home. As healthcare systems continue emphasizing patient autonomy, long-term disease management, and digital monitoring, homecare settings are expected to remain a major application area for CGM adoption.

Key Questions Answered in this Report

Q1. What is driving the growth of the United States CGM market?

The market is growing due to rising diabetes prevalence, increasing demand for real-time glucose monitoring, expanding homecare adoption, technological innovation in sensors, and wider use of connected diabetes management systems.

Q2. What does a continuous glucose monitoring system do?

A CGM system continuously tracks glucose levels throughout the day and night, helping users monitor fluctuations, improve treatment decisions, reduce fingerstick dependence, and manage diabetes more effectively.

Q3. Why are CGM devices becoming more popular in homecare settings?

CGM devices support independent diabetes management at home by providing continuous monitoring, alerts, remote data sharing, convenience, and better understanding of how lifestyle and treatment affect glucose levels.

Q4. How is technology improving the CGM market in the United States?

Technology is improving the market through more accurate sensors, longer wear durations, smartphone integration, cloud connectivity, remote monitoring, and better compatibility with insulin pumps and digital health platforms.

Q5. What are the main challenges in the United States CGM market?

Major challenges include device affordability, reimbursement complexity, user training requirements, data interpretation difficulties, device acceptance issues, and the need for continued patient education and technical support.

Market Segmentation

Component

• Sensors
• Transmitters
• Receivers

End User

• Hospitals
• Homecare Settings
• Others

States

• California
• Texas
• New York
• Florida
• Illinois
• Pennsylvania
• Ohio
• Georgia
• New Jersey
• Washington
• North Carolina
• Massachusetts
• Virginia
• Michigan
• Maryland
• Colorado
• Tennessee
• Indiana
• Arizona
• Minnesota
• Wisconsin
• Missouri
• Connecticut
• South Carolina
• Oregon
• Louisiana
• Alabama
• Kentucky
• Rest of the United States

All the Key players have been covered with 5 Viewpoints

• Overviews
• Key Person
• Recent Developments
• SWOT Analysis
• Revenue Analysis

Key Players Analysis

• Abbott Laboratories
• Roche
• Tandem Diabetes Care
• DexCom Inc.
• Senseonics Holdings, Inc.
• Ypsomed Holding AG
• Medtronic Plc.
• i-Sens Inc.

Report Details: